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Abstract
Background: Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vacci-
nation programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential
impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden
of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently
licensed HPV vaccines.
Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection
and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA-
positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16INK4a immunohistochemistry. For cervi-
cal cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and
p16INK4a biomarkers.
Results: The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of
cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile,
60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases.
Conclusions: Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical
cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
Human papillomavirus (HPV)-related cancers remain a major
cause of cancer both in men and women. Worldwide, HPV infec-
tion causes up to 4.5% (640 000 cases) of all new cancer cases
worldwide (8.6% females; 0.9% males), representing 29.5% of all
infection-related cancers (1,2).
The global burden of cervical cancer (530 000 cases) is sub-
stantially higher than that of HPV-related cancers other than
cervix (113 000 cases) (1,2). However, an increase in the inci-
dence of anal and HPV-related head and neck cancers (HNCs)
has been noted in recent decades (3–6).
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HPV infection is unequivocally linked to almost all cervical
cancer cases (95% of cases) and a large proportion of anal
cancer cases (88% of cases attributable to HPV) (2). HPV is
also causally associated with a varying percentage of cancers
of the vulva, vagina, penis, and a subset of HNCs, particularly
tonsillar cancer (7,8). Within the spectrum of HPV oncogenic
types, HPV 16 is the most prevalent in all HPV-related cancer
sites. Based on previous analytical studies that demonstrated
HPV to be a necessary cause of cervical cancer, HPV attribution
has been based on the detection of HPV DNA alone. However,
additional carcinogenic pathways other than HPV are sus-
pected for anal and vaginal cancers, and validated for vulvar,
penile, and HNCs. Thus, the identification of HPV DNA com-
bined with E6/E7mRNA, a marker of viral transcriptional activ-
ity, or p16INK4a, a cell surrogate marker of HPV carcinogenic
transformation, provides a more accurate, although conserva-
tive, assessment of oncogenic activity of the virus in the spe-
cific sites (9–11).
Prophylactic HPV vaccines have been introduced worldwide
since 2006, with a high efficacy and safety record in the preven-
tion of vaccine-type HPV infection and disease. Further, the HPV
vaccines show a high effectiveness profile on prevalent infections,
precancerous lesions, and genital warts, as well as a robust herd-
protection effect in nonvaccinated sexual partners with a high
vaccine coverage rate (12,13). Currently, three HPV vaccines are
commercially available (bivalent, tetravalent, and nonavalent). All
three contain virus-like particles (VLPs) of HPVs 16/18. The tetra-
valent vaccine also contains VLPs from HPVs 6/11. The nonava-
lent vaccine additionally protects against HPVs 31/33/45/52/58.
The World Health Organization recognizes the importance
of HPV-related diseases as global public health threats and has
reiterated the recommendation to include HPV vaccines in
national immunization programs (14). By October 2014, 80 coun-
tries (mainly high- and upper-middle income) had implemented
HPV vaccination programs and 47 million women had received
the full course of the vaccine. Even more, it has been estimated
that approximately 379 000 cases of cervical cancer and 156 000
deaths could be averted in the 47 million fully vaccinated
women by age 75 years, assuming lifelong protection (15).
The evidence suggests that the combination of high HPV
vaccination coverage in adolescents together with high cervical
screening coverage (followed by adequate treatment of the
lesions detected by screening) can eliminate cervical cancer as a
public health problem. As a result, it has been established that
one of the greatest priorities and challenges in global health is
to give access to HPV vaccination and cervical screening to the
majority of women around the world. The availability of a wide
range of cervical screening techniques (cytology, HPV-detection
techniques, visual inspection with acetic acid) and HPV vaccina-
tion options (bivalent, tetravalent, and nonavalent vaccines
with two- or three dose schedules) leads to an increase in the
complexity of decision making regarding the combination of op-
timal prevention strategies in each region of the world.
To evaluate the potential impact of HPV vaccines in the re-
duction of HPV-related disease burden and to help formulate
recommendations on HPV prevention, we estimated the HPV
type distribution and burden of cancer cases attributable to the
HPV types included in the nonavalent vaccine. For this we used
new data derived from a large international study that provided
information on HPV DNA, mRNA, and p16INK4a from formalin-
fixed paraffin-embedded (FFPE) tissue of anogenital and HNC
sites.
Materials and Methods
To estimate the prevalence and relative contribution (RC) of the
types included in licensed HPV vaccines in HPV-related cancers,
we used updated data from an international project designed
and coordinated by the Catalan Institute of Oncology (ICO)
(Barcelona, Spain) in collaboration with DDL Diagnostic



























































Figure 1. Anatomical sites included from each country. The number of cancer samples included at each anatomical site varies among countries.
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Study Design
The project is a cross-sectional study. Case recruitment proto-
cols were previously described (5,16–20). Briefly, consecutive (or
randomly selected) FFPE specimens processed in pathology lab-
oratories were obtained from hospital pathology archives in
50 countries (Figure 1). Other variables collected were sex, age at
diagnosis, year at diagnosis, and original histological diagnosis.
This article uses information from 11 228 cervical, 496 anal, 408
vaginal, 1709 vulvar, 1010 penile, 1090 oropharyngeal, 1264 oral
cavity, and 1042 laryngeal cancer cases. Table 1 summarizes the
main characteristics of the tumor series.
Pathology and Laboratory Procedures: FFPE Block
Processing, Histological Evaluation, and HPV Detection
and Genotyping
FFPE blocks were processed under strict conditions. At least five
paraffin sections were systematically obtained for each block
(sandwich method). First and last sections were used for histo-
pathological evaluation after hematoxylin and eosin staining.
The intermediate sections were used for HPV DNA and mRNA
testing. HPV DNA detection was performed by polymerase chain
reaction (PCR) with SPF-10 broad-spectrum primers. The ampli-
fied PCR products were tested for the presence of HPV DNA us-
ing a DNA enzyme immunoassay (DEIA) that recognized at least
54 mucosal HPV genotypes. DNA quality was evaluated by PCR
testing for the human tubulin in all HPV DNA-negative vaginal,
anal, and HNCs, and a subset of samples of cervical, vulvar, and
penile cases (almost all HPV DNA-negative cervical cancer cases
were due to technical artifacts, and 10% of the vulvar and penile
cancers were due to poor DNA quality). Vaginal, anal, and HNCs
that were negative both for HPV DNA and tubulin were excluded
from the final analyses. Amplimers testing positive for viral
DNA by DEIA were genotyped with a reverse hybridization line
probe assay—LiPA25 that detects 25 HPV types (HPVs 6/11/16/
18/31/33/34/35/39/40/42/43/44/45/51/52/53/54/56/58/59/66/68/70/
74) (21). Sequence analysis was performed to characterize HPV
DEIA-positive samples with unknown types and to disentangle
HPVs 68/73 because the LiPA system is unable to separate these
types. If no HPV type could be attributed after DNA sequencing,
the HPV type was labeled as undetermined.
With the exception of cervical cancer cases, all HPV DNA-
positive samples, and a random selection of HPV DNA-negative
cases for quality control, were further subjected to HPV E6*I
mRNA detection, a biomarker of HPV viral transcriptional activ-
ity, and p16INK4a immunohistochemistry, a cellular surrogate
marker for HPV carcinogenic transformation. The E6*I mRNA as-
say targets 20 HPV types (HPVs 16/18/26/31/33/35/39/45/51/52/
53/56/58/59/66/67/68/70/73/82). For each case, type-specific E6*I
mRNA PCR was performed for all types detected by the SPF-10
PCR/DEIA/LiPA25 system that had at least one of the mRNA tar-
geted types, and additionally for HPV 16. p16INK4a was detected
using the CINtec histology kit (clone E6H4, Roche mtm laborato-
ries AG, Germany) following the manufacturer’s protocol. A pat-
tern of diffuse staining of more than 25% stained cells (nuclear
and cytoplasmic) was considered positive.
Statistical Analysis
For cervical cancer, RC of the nine types included in the nonava-
lent vaccine was expressed as the proportion of women positive
for a specific type among all HPV DNA-positive samples. HPV
prevalence was calculated as those positive among all tested
samples. For the other cancer sites, RC estimates were based on
the combined positivity for HPV DNA and (E6*I mRNA or
p16INK4a). HPV prevalence indicates those positive for HPV DNA
and (E6*I mRNA or p16INK4a) among all those tested. For all sites,
information on multiple infections was added to single types in
accordance with a proportional weighting attribution (22,23).
RCs by region, sex, and age at diagnosis were determined. To
evaluate differences among proportions, we used the most suit-
able test (chi-squared, Fisher), adjusting for multiple compari-
sons (Bonferroni–Holms) when necessary. Trend test analysis
for proportions was used to evaluate trends by age at diagnosis.
The statistically significant P value was set at .05.
We further estimated the potential preventable number of
cases per year by applying the estimated proportions attributed
to HPV to the number of cases estimated to occur each year as
reported by de Martel et al. (24).
Results
Squamous cell carcinomas (SCCs) accounted for more than 90%
of cases reviewed, with the exception of vaginal cancer. Most
cases were from Europe and the Americas (Table 1). Cervical
cancer cases were diagnosed at younger ages (mean age ¼
51.1 years) compared to the other sites (mean ages ranging from
61.0 to 68.5 years).
Overall HPV and type-specific prevalence results are
reported in Table 1 and Figures 2 and 3. The HPV prevalence for
all types combined was 84.8% in cervical cancer cases (HPV DNA
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Figure 2. Overall HPV positivity for HPV DNA and HPV DNA þ (E6*I mRNA or
p16INK4a) by anatomical site. 95% CI ¼ 95% confidence interval (one-sided, 97.5%
CI calculated when appropriate; HPV ¼ human papillomavirus. For more details,
please see the methodological section from Castellsague et al. 2016; de Sanjose
et al. 2010; de Sanjose et al. 2013; Alemany et al. 2014, Alemany et al. 2015, and
Alemany et al. 2016 (5,16–20).
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and “E6*I mRNAþ or p16INK4aþ”) for all types combined was
82.6% anal, 71.0% vaginal, 27.7% penile, 24.6% vulvar, 22.4% oro-
pharyngeal, 4.4% oral cavity, and 3.5% laryngeal cancers. When
comparing HPV DNA detection estimates to the ones adding
E6*I mRNA and p16INK4a, a reduction of the proportion of cases
attributed to HPV were higher for oral cavity and larynx (per-
centage reduction¼ 40.5% and 38.6%, respectively) than penis,
vulva, oropharynx, anus, and vagina (percentage reduc-
tion¼ 16.3%, 14.0%, 10.0%, 6.4% and 4.4%, respectively), (P< .05
for oral cavity, larynx, penis, vulva, and anus).
Among HPV positives, RC of the nine types was 95.7% in the
anus, followed by oropharynx (95.1%), vulva (92.8%), oral cavity
(92.7%), cervix (89.3%), penis (88.1%), vagina (85.6%), and larynx
(77.8%) (Tables 2 and 3 and Figure 2). RC of HPVs 16/18 was espe-
cially prominent in oral cavity, oropharyngeal, and anal cancer
sites (90.9%, 90.5%, and 87.2%, respectively), mostly attributable
to HPV 16 (90.9%, 88.5%, and 83.7%, respectively). RCs of HPVs
16/18 in other anogenital and HNCs was 79.0% in the vulva, fol-
lowed by penis (76.6%), cervix (70.9%), vagina (64.3%), and larynx
(52.8%). The additional contribution of HPVs 31/33/45/52/58 was
higher in the larynx (22.2%), vagina (21.0%), and cervix (18.3%)
compared to other cancer sites (Tables 2 and 3). HPV 16 was by
far the most frequently detected genotype across all anatomical
sites. RCs by individually tested types are detailed in
Supplementary Material Table 1 (available online). RC of the
nine HPV types was significantly higher when taking into ac-
count the combined detection of HPV DNA, and E6*I mRNA or
p16INK4a for vulvar and oropharyngeal cancers as compared to
HPV DNA detection alone (Tables 2 and 3).
HPV RCs by region are provided in Figure 4 and
Supplementary Material Tables 2 and 3 (available online).
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Figure 3. Worldwide HPV prevalence and relative contribution in HPV-related cancers, by sex. 95% CI ¼ 95% confidence interval (one-sided, 97.5% CI calculated when
appropriate); Cervix ¼ based on HPV DNA; HPV ¼ human papillomavirus; Other locations ¼ based on information on three markers (HPV DNA + (E6*I mRNA or
p16INK4a)); Prev ¼ prevalence and type-specific relative contribution estimations. For more details, please see the methodological section from Castellsague et al. 2016;
de Sanjose et al. 2010; de Sanjose et al. 2013; Alemany et al. 2014, Alemany et al. 2015, and Alemany et al. 2016 (5, 16–20).
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all regions. Within cervical cancer, HPV 16 RC ranged from
47.3% (Africa) to 65.5% (Europe); in vulvar cancer from 66.7%
(Americas) to 87.5% (Africa); in vaginal cancer from 46.2%
(Africa) to 66.9% (Europe); in anal cancer from 66.7% (Africa) to
87.3% (Europe), in penile cancer from 71.4% (Africa) to 78.9%
(Europe), in oropharyngeal cancer from 78.1% (Americas) to
94.7% (Asia and Oceania), in oral cavity cancer 90.9% (Americas
and Europe), and in larynx cancer from 0.0% (Africa based on
small number of samples) to 58.3% (Europe). Although cumula-
tive RC of the nine types varied slightly by region, differences
were not statistically significant when comparing regions with
world data. The only exception was observed in cervical cancer
in Africa and Asia and Oceania (World—89.3%, Africa—86.3%,
Asia and Oceania—91.2%; P< .05).
Differences by sex were not detected in the combined RC of
HPVs 16/18, HPVs 31/33/45/52/58, or the nine HPVs for anal and
HNCs, except for a higher RC of HPVs 16/18 in male oropharynx
(P< .05) (Figure 3).
No specific nine HPV RC age trends were observed by cancer
site, except in the cervix (Supplementary Material Table 4, avail-
able online), where the combined RC of the nine types decreased
with age (P< .001); mainly explained by the decrease of HPVs 16/
18/45 in older ages (more details in Serrano et al. 2012) (25).
The potentially preventable fraction of the nonavalent HPV
vaccine would be around 50% worldwide, taking into account
our type-specific prevalence estimates and the estimated num-
ber of incident cases at HPV-related cancer sites provided by de
Martel et al. (24). These would include most cervical and anal
cancers and a substantial fraction of vaginal, penile, vulvar, and
HNCs (Table 4).
Discussion
This comprehensive analysis of the contribution of HPV vaccine
types in selected anogenital and HNCs provides robust
estimates to be used to monitor the vaccine impact worldwide.
We present data from all HPV-related sites, updating the num-
ber of the cervical series, and adding the evaluation of molecu-
lar and immunohistochemistry markers of viral activity beyond
HPV DNA detection. In the absence of a unique carcinogenic
pathway and of detection of specific infections leading to can-
cer, the addition of these markers increases our ability to attrib-
ute causality (8,11). Our data confirm the biological role of HPV
in the great majority of HPV DNA-positive anogenital and oro-
pharyngeal cancers, and to a much lesser extent in oral cavity
and laryngeal cancers.
We have estimated that the combined detection of HPV DNA
and (E6*I mRNA or p16INK4a) confirms that the addition of HPVs
31/33/45/52/58 to the current vaccine types (HPVs 16/18/6/11),
could prevent almost 96% of the HPV-positive cancers of the
anus, vulva (93%), cervix (90%), penis (88%), vagina (86%), oro-
pharynx (95%), oral cavity (93%), and larynx (78%). A marked
heterogeneity in the incremental HPV-related preventable frac-
tion added by the nonavalent vaccine compared to bivalent and
tetravalent vaccines was observed, ranging from 8.0% (anal) to
21.0% (vaginal) in anogenital cancer sites, and from 1.8% (oral
cavity) to 22.2% (larynx) in HNC sites.
Similar to previous data, overall HPV prevalence was lower
for vulvar (24.6%), penile (27.0%), oral cavity (4.4%), laryngeal
(5.7%), and oropharyngeal (22.4%) cancers, compared with vagi-
nal (71.0%), anal (82.6%), and cervical (84.8%) cancers (2).
Therefore, overall the nonavalent vaccine could prevent 22.8%
of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal, and
90% of cervical cancer cases, 21.3% of oropharynx, 4.0% of oral
cavity, and 2.7% of larynx cancers cases. Some of our prevalence
estimates are lower than those published in previous meta-
analyses (6,26) or in series using similar protocols (27–30). These
differences were expected, as we used a more restrictive proto-
col in terms of HPV attribution by adding additional markers.
This study included cases from numerous countries, some of
which had scarce data published. This is particularly relevant in
Table 3. Worldwide relative contribution of HPVs 16/18/31/33/45/52/58/6 and 11 in head and neck HPV-related cancers
HPV type




(n¼ 243) DNAþ(n¼ 93)
and (E6*I mRNA/
p16INK4a)




RC% (95% CI) RC% (95% CI) RC% (95% CI) RC% (95% CI) RC% (95% CI) RC% (95% CI)
Combined nine HPV types† 90.0 (85.8 to 93.3) 95.1 (91.5 to 97.4) 81.7 (72.4 to 89.0) 92.7 (82.4 to 98.0) 83.1 (71.0 to 91.6) 77.8 (60.8 to 89.9)
HPVs 16/18 85.2 (80.4 to 89.2) 90.5 (86.1 to 93.9) 72.0 (61.8 to 80.9) 90.9 (80.0 to 97.0) 57.6 (44.1 to 70.4) 52.8 (35.5 to 69.6)
HPVs 31/33/45/52/58 8.6 (3.8 to 16.2) 4.5 (2.3 to 8.0) 4.4 (2.3 to 7.6) 1.8 (0.0 to 9.7) 16.9 (8.4 to 29.0) 22.2 (10.1 to 39.2)
Specific HPV type
HPV 16 83.4 (78.4 to 87.6) 88.5 (83.8 to 92.2) 70.9 (60.6 to 79.9) 90.9 (80.0 to 97.0) 50.8 (37.5 to 64.1) 44.4 (27.9 to 61.9)
HPV 18 1.8 (0.6 to 4.3) 2.1 (0.7 to 4.7) 1.1 (0.0 to 5.8) 0.0 (0.0 to 6.5) 6.8 (1.9 to 16.5) 8.3 (1.8 to 22.5)
HPV 31 0.0 (0.0 to 1.4) 0.0 (0.0 to 1.5) 0.0 (0.0 to 3.9) 0.0 (0.0 to 6.5) 3.4 (0.4 to 11.7) 2.8 (0.1 to 14.5)
HPV 33 3.3 (1.5 to 6.2) 3.3 (1.4 to 6.4) 0.0 (0.0 to 3.9) 0.0 (0.0 to 6.5) 3.4 (0.4 to 11.7) 2.8 (0.1 to 14.5)
HPV 45 0.4 (0.0 to 2.0) 0.4 (0.0 to 2.3) 0.0 (0.0 to 3.9) 0.0 (0.0 to 6.5) 8.5 (2.8 to 18.7) 13.9 (4.7 to 29.5)
HPV 52 0.0 (0.0 to 1.4) 0.0 (0.0 to 1.5) 7.6 (3.1 to 14.9) 0.0 (0.0 to 6.5) 0.0 (0.0 to 6.1) 0.0 (0.0 to 9.7)
HPV 58 0.7 (0.1 to 2.6) 0.8 (0.1 to 2.9) 1.1 (0.0 to 5.8) 1.8 (0.0 to 9.7) 1.7 (0.0 to 9.1) 2.8 (0.1 to 14.5)
HPV 6 0.4 (0.0 to 2.0) 0.0 (0.0 to 1.5) 0.0 (0.0 to 3.9) 0.0 (0.0 to 6.5) 6.8 (1.9 to 16.5) 2.8 (0.1 to 14.5)
HPV 11 0.0 (0.0 to 1.4) 0.0 (0.0 to 1.5) 1.1 (0.0 to 5.8) 0.0 (0.0 to 6.5) 1.7 (0.0 to 9.1) 0.0 (0.0 to 9.7)
†Nine HPV types includes the ones in nonavalent HPV vaccine: HPVs 16/18/31/33/45/52/58/6/11. 95% CI ¼ 95% confidence interval (one-sided, 97.5% CI calculated when
appropriate); DNAþ ¼ cases that tested positive for HPV DNA; E6*I mRNA/p16INK4a ¼ cases that tested positive for HPV DNAþ (E6*I mRNA positive or p16INK4a positive;
HPV ¼ human papillomavirus; N ¼ number of cases; RC ¼ relative contribution. E6*I mRNA was performed in HPV-DNA–positive samples for types: HPVs 16/18/26/31/
33/35/39/45/51/52/53/56/58/59/66/67/68/70/73/82. Type-specific RC estimations are estimated among HPV DNA positive and among HPV DNA positive þ (E6*I mRNA pos-
itive or p16INK4a positive). For more details, please see the methodological section from Castellsague et al. 2016 (5).
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HNC sites where a substantial variability in the HPV-related at-
tribution has been observed across regions (2). Contrary to this,
our series have a distinctive limitation on samples from areas
reported to have an increased trend of HPV-driven HNCs, such
as the United States and Northern Europe, where higher
attributable fractions in HNCs have been recently reported (30).
Although the exclusive use of HPV DNA results in higher attri-
bution to HPV (30), when adding other biomarkers the attribu-
tion was reduced to 67.2% in oropharynx SCC, 5.9% in oral
cavity SCC, and 1.7% in larynx SCC (27–29).
Table 4. Preventable fraction of human papillomavirus (HPV)-related cancer cases per year
HPV-related cancer site Incident cases, No.*
Cases attributable
to HPV, No. Nine HPV types, %
Cases attributable
to HPV, No. Nine HPV types, %
Cervix uteri 530 000 405 450† 76.5† 477 000‡ 90.0‡
Anus 40 000 31 600 79.0 31 600 79.0
Vulva 34 000 7752 22.8 7752 22.8
Vagina 15 000 9105 60.7 9105 60.7
Penis 26 000 6370 24.5 6370 24.5
Oropharynx 96 000 20 448 21.3 20 448 21.3
Oral cavity 200 000 8000 4.0 8000 4.0
Larynx 160 000 4320 2.7 4320 2.7
Total HPV-related sites 1 101 000 493 045 564 595
Potentially preventable cases, % 44.8% 51.3%
*Source: de Martel, 2017
†Assumption: 85% HPV DNA-positivity and 90% relative contribution (RC) of nine HPV types.











































Figure 4. HPV relative contribution of types included in licensed HPV vaccines in HPV-related cancers, by region. 95% CI ¼ 95% confidence interval (one-sided, 97.5% CI
calculated when appropriate); HPV ¼ human papillomavirus; n ¼ number of cancer cases represented in the region. Type-specific relative contribution estimations:
Cervix ¼ based on HPV DNA positive; Other locations ¼ based on information on three markers (HPV DNA positive þ (E6*I mRNA or p16INK4a)). For more details, please
see the methodological section from Castellsague et al. 2016; de Sanjose et al. 2010; de Sanjose et al. 2013; Alemany et al. 2014, Alemany et al. 2015, and Alemany et al.
2016 (5, 16–20).
8 of 11 | JNCI Cancer Spectrum, 2019, Vol. 2, No. 4
Worldwide incidence rates at HPV-related cancer sites
other than the cervix are much lower than that observed for
cervical cancer. However, incidence rates in anal, vulvar, and
HPV-related HNCs are increasing, probably linked to changes
in sexual behavior, tobacco and alcohol consumption, and in
cervical cancer screening policies (2–4).The large contribution
of HPV infection, mainly of HPV 16, the absence of well-
established screening instruments, and algorithms for the
detection of HPV-related cancer cases other than the cervix,
and the current evidence on HPV vaccine efficacy, reinforces
the role that HPV vaccines can play in primary prevention of
HPV-related lesions. Moreover, even if a higher impact of HPV
vaccination would be expected in cervical and anal cancer, the
confirmed increasing trends of HNCs attributable to HPV could
be translated to a high number of cases prevented by vaccina-
tion despite the low proportion of HPV-related cases estimated
for these sites (2).
HPV 16 was the most important oncogenic type (60% in
anogenital cancer sites, and 44% to 91% in HNCs). The inclusion
of additional markers increased the HPV 16 RC in vulvar, penile,
oral cavity, and oropharyngeal cancers, and confirmed the caus-
ative role for other, less frequently occurring mucosal HPV
types. Some non-HPV 16 types, usually involved in cervical can-
cer, are also related to other cancers of the genital tract and
HNCs, but to a lesser extent. Although HPV18 is reported to be
the second most common type in cervical cancer, variations
were observed in other cancer sites. HPV 33 follows HPV 16 in
vulvar and oropharyngeal cancers, HPV 31 in vaginal cancer,
HPVs 31/45 in penile cancer, HPVs 18/33 in anal cancer, HPV 58
in oral cavity cancer, and HPVs 18/45 in laryngeal cancers.
However, results in oral cavity and larynx should be interpreted
with caution because of the limited number of cases included.
HPVs 6/11, contribution is minimal in the overall burden of
HPV-related cancers, although they still rank relatively high in
penile and anal cancer.
We found little heterogeneity by geographical region, sex,
and age at diagnosis. Regional differences in the HPV RCs were
significant only for cervical and oropharyngeal cancers. For cer-
vical cancer a significantly higher contribution was observed in
Asia and Oceania, and for oropharyngeal cancer a significantly
higher contribution was observed in Europe compared to the
Americas. However, further research will be necessary to pro-
vide robust estimates by region for noncervical lesions. Overall,
HPV RC estimates were higher in women than in men, although
differences were significant only for oropharyngeal cancer. The
magnitude of RCs decreased with increasing age for all cancer
sites. RC age trends were evaluated for the nine types combined.
A similar analysis for individual HPV types was not possible be-
cause of the limited number of cases in cancer sites other than
the cervix. Assessment of multiple infections was possible by
means of a proportional weighting attribution (22,23). A decrease
in the proportion of cases with multiple infections was observed
in oropharyngeal cancers. The proportion of cases with multiple
infections (0.4%) was 15 times lower than in cervical cancer
(6.3%). It is unknown why there is this difference in the propor-
tion of multiple infections, but it could be explained by differen-
ces in cell susceptibility to HPV infection in different tissues.
Despite the large sample size and the strong design, this
study is not free of limitations. The principal one is that while
the presence of HPV DNA was assessed in all tested samples,
the two additional biomarkers E6*I mRNA and p16INK4a were
assessed only in HPV DNA-positive samples as well as in a
small fraction of HPV DNA-negative cases (of which 10% were
mRNA positive), and not for all HPV genotypes. Therefore, we
cannot completely rule out that we are not excluding some
truly HPV-driven cases because of imperfect detection of the HPV
DNA test, although we used the most sensitive test available to
date. Moreover, although HPV E6*I mRNA and p16INK4a together
with HPV DNA are well established markers in research and even
in clinical settings for specifically attributing one case to be etio-
logically related to the virus, we are missing other potential
approaches such as laser capture microdissection that can specif-
ically analyze the markers in tumoral cells instead of the whole
paraffin-embedded tissue block section that may be even more
specific. However, we have applied the most suitable markers
analyses taking into account the design of the study, a large epi-
demiological biorepository. Another limitation of the study was
the small number of samples included from some regions (such
as Africa) and ages, thus restricting the validity of our results for
certain regions and ages. Finally, the use of fresh tissue samples
would have been preferred but unrealistic to obtain when includ-
ing such a large number of countries. Additionally, the studies
reflect the epidemiology of each country and the impact of poten-
tial variation in screening or other environmental modifications
in HPV attribution is difficult to fully evaluate in this study.
Finally, for the estimated preventable fraction we make several
vaccine effects assumptions: efficacy for all HPV-related cancers,
long-term duration of the protection, among others.
Our estimations suggest that if HPV vaccination programs
with the nonavalent HPV vaccine are effectively implemented,
around 90% of cervical cancers and 50% of all HPV cancer sites
related to HPV could be prevented.
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